ClinicalTrials.gg
Enrolling by invitationNCT04996316Updated Feb 13, 2026

MammoScreen Breast Cancer Risk Assessment and Decision Aid for Breast Cancer Screening and Referrals

An observational study in Breast Carcinoma, sponsored by OHSU Knight Cancer Institute. Enrolling by invitation at 1 site in United States. Open to female participants aged 40 Years to 74 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-13.

Sponsored by OHSU Knight Cancer Institute · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
1,141
Ages
40 Years to 74 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 29 studies in Breast Neoplasms by OHSU Knight Cancer Institute — 3 open to participants now, 4 under way, none of them phase 3. Breast Neoplasms · OHSU Knight Cancer Institute.

Started
2022
with 2 others
Observational
5 of 29
1 open now
Registered
24th of 29
by date

Among the 29 studies in Breast Neoplasms by OHSU Knight Cancer Institute, this one is one of 3 that started in 2022, is one of 5 observational ones, and was the 24th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

3 of the 29 studies in Breast Neoplasms by OHSU Knight Cancer Institute are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 40 Years to 74 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in Breast Neoplasms by OHSU Knight Cancer Institute, or all of them as a file.
02

Study summary

This study collects information to implement MammoScreen for Breast Cancer Screening and Referrals. MammoScreen is a risk assessment questionnaire that identifies individuals at average and increased risk for breast cancer and guides their screening decisions.

Read the detailed description

PRIMARY OBJECTIVES:

I. Uptake of MammoScreen (the proportion of women who enroll and use MammoScreen, also referred to as Reach.

II. Identification of women with above-average risk for breast cancer by MammoScreen integrated with the electronic health record (EHR).

SECONDARY OUTCOMES:

I. Rates of mammography screening referral. II. Screening completed and mammography results stratified by risk category. III. Among those who meet criteria, genetic counseling referral, visit completed and genetic test done.

OUTLINE:

CLINICAL STAFF: During development some clinical team members will participate in usability testing (up to 30 minutes) of the electronic health record interface with MammoScreen. Some participants will undergo training sessions of about 20 minutes, then participate in interviews lasting up to 30 minutes at baseline prior to MammoScreen launch. Clinical staff also participate in interviews up to 30 minutes after MammoScreen launch during years 2-4. Participants complete surveys during the maintenance phase about six months after the last reminders are sent.

PATIENTS: Patients (enrolled from OHSU IMC) participate in interviews lasting up to 1 hour. Patients medical records are reviewed. Patients will be invited via MyChart to use the MammoScreen. Reminders will be sent via MyChart to non-respondents at 2 and 4 weeks. Patients will use MammoScreen one time right after enrollment. Some patients may also participate in interviews up to 1 hour each during years 3-5.

03

Conditions studied

  • Breast Carcinoma

Browse trials for

04

Who can participate

Ages eligible
40 Years to 74 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Women between the ages of 40 and 74

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women between the ages of 40 and 74
  • Enrolled in MyChart
  • Able to read English

Exclusion criteria

Exclusion Criteria:

  • Personal history of breast or ovarian cancer
  • Currently Pregnant
  • Currently in Hospice
05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
1,141 participants (estimated)

Groups and cohorts

  • Clinical staff (interview, training, survey)

    Before implementation, some participants will complete usability testing of the interface in the electronic health record and MammoScreen. Participants undergo training sessions over 20 minutes and participate in interviews over 30 minutes at baseline, prior to MammoScreen launch. Clinical staff also participate in interviews over 30 minutes after MammoScreen launch during years 2-4. Participants complete surveys during the maintenance phase, about six months after the last reminders are sent.

    Other: Electronic Health Record Review · Other: Interview · Other: Survey Administration · Other: Training and Education

  • Patients (interview, MammoScreen)

    Patients participate in interviews up to 1 hour. Patients medical records are reviewed. Patients use the MammoScreen at enrollment. Some Patients will also participate in interviews up to 1 hour, each during years 3-5.

    Other: Electronic Health Record Review · Other: Interview · Other: Media Intervention

Interventions

  • OtherElectronic Health Record Review

    Health record reviewed

  • OtherInterview

    Participate in interview

  • OtherMedia Intervention

    Use MammoScreen

  • OtherSurvey Administration

    Complete survey

  • OtherTraining and Education

    Undergo training

06

What researchers measure

Primary outcomes

  1. Uptake of MammoScreen

    Defined as the proportion of women who enroll and use MammoScreen. Proportions of invitations for newly eligible women and uptake of MammoScreen during the maintenance period, overall and by clinical team, will be characterized along with 95% exact confidence intervals.

    Time frame: Up to 5 years

  2. Number of women with above-average risk for breast cancer identified by MammoScreen integrated with the electronic health record

    Time frame: Up to 5 years

Secondary outcomes

  1. Rates of mammography screening referral

    Time frame: Up to 5 years

  2. Screening completed

    The proportions of patients who open, and complete MammoScreen and 95% confidence intervals will be calculated. Demographic and clinical characteristics of patients who complete MammoScreen versus those who do not will be compared using a two-sample t-test or chi-square test as appropriate. Variation in completing MammoScreen by patient (e.g., age) and provider characteristics (e.g., panel size) will be explored.

    Time frame: Up to 5 years

  3. Mammography results

    Will be stratified by risk category. Will be analyzed similarly using proportions and 95% confidence intervals, and a regression model if allowed by data.

    Time frame: Up to 5 years

  4. Number of above average risk MammoScreen users who received a genetic counseling referral

    Will be analyzed similarly using proportions and 95% confidence intervals, and a regression model if allowed by data.

    Time frame: Up to 5 years

  5. Number of above average risk MammoScreen users who completed a genetic counseling visit

    Time frame: Up to 5 years

  6. Number of above average risk MammoScreen users who had a genetic test done

    Time frame: Up to 5 years

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2022 to primary completion in Apr 2025, 31 months.

Of 1,193 non-industry observational studies under Breast Neoplasms, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 139. This study's 31 months is below that.

Counting every sponsor, half of 1,382 studies reached it within 55 months; a quarter within 25 and three quarters within 126.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 2, 2021
First posted
Aug 9, 2021
StartActual
Sep 7, 2022
Primary completionActual
Apr 30, 2025
CompletionEst.
Aug 31, 2026
Last update
Feb 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04996316
Collaborators
Agency for Healthcare Research and Quality (AHRQ), Oregon Health and Science University
Responsible party
Karen Eden, Ph.D. (Principal Investigator, OHSU Knight Cancer Institute) — Principal investigator
First posted
Aug 9, 2021
Start date
Sep 7, 2022
Primary completion
Apr 30, 2025
Completion
Aug 31, 2026 (estimated)
Last update
Feb 13, 2026

Study contacts

Karen Eden, Ph.D.
principal investigator · Department of Medical Informatics and Clinical Epidemiology, OHSU Knight Cancer Institute

Oversight

FDA-regulated drug
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion